重型或中型重型血友病A既往治疗患者的因子VIII产品与抑制物发生:一项系统综述
该系统综述纳入41个独立队列,观察19 157人年,39例既往治疗的重型血友病A患者发生新发抑制物,总发生率为每1000人年2.06(95%CI 1.06-4.01)。部分重组因子VIII产品可能与免疫原性增加相关,但抑制物发生率低及研究设计差异可导致风险估计显著变异。
要点
- 既往治疗的重型血友病A患者抑制物总发生率为每1000人年2.06(95%CI 1.06-4.01)。
- 部分重组因子VIII产品的汇总发生率较高,如Refacto为每1000人年12.05(95%CI 1.53-94.78)。
- 抑制物发生率低及研究设计差异可导致风险估计显著变异。
核心结论
- 结果提示部分产品可能与免疫原性增加相关,但抑制物发生率低及研究设计差异可导致风险估计显著变异。
研究设计与样本
- 系统综述与Meta分析,纳入报告基线FVIII活性<0.02 IU mL-1且接受FVIII治疗至少50天的患者新发抑制物的纵向研究,共41个独立队列。
主要发现
- 39例患者在19 157人年观察期间发生新发抑制物,总发生率为每1000人年2.06(95%CI 1.06-4.01)。
- Advate组汇总发生率为每1000人年0.99(95%CI 0.37-2.70)。
- Kogenate/Helixate组汇总发生率为每1000人年5.86(95%CI 0.25-134.92)。
- Kogenate FS/Helixate NexGen组汇总发生率为每1000人年1.35(95%CI 0.66-2.77)。
- Refacto组汇总发生率为每1000人年12.05(95%CI 1.53-94.78),Refacto AF组为每1000人年4.64(95%CI 0.82-26.43)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 既往治疗患者中抑制物发生率低。
- 研究设计差异可导致风险估计显著变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Data on product-related immunogenicity in previously treated haemophilia A patients is scarce. A systematic review and meta-analysis of all currently available evidence was conducted. The overall incidence rate was 2.06 per 1000 person-years (95% confidence interval: 1.06-4.01). Some recombinant factor VIII products were associated with increased immunogenicity. SUMMARY: Background Patients with severe hemophilia A who have been treated extensively with factor VIII products have a low but potentially serious risk of inhibitor development. It is unknown why these patients develop inhibitors, and data on product-related immunogenicity are scarce. Aims To summarize the currently available evidence on the relationship between inhibitor development and recombinant FVIII product type in previously treated patients (PTPs) with severe hemophilia A. Methods Longitudinal studies were included that reported on de novo inhibitor formation in patients with baseline FVIII activity levels of < 0.02 IU mL-1 who had been treated with FVIII for at least 50 days. Pooled incidence rates of inhibitor development according to product types were calculated with a random intercept Poisson regression model. Results Forty-one independent cohorts were included; 39 patients developed de novo inhibitors during 19 157 person-years of observation. The overall incidence rate was 2.06 per 1000 person-years, with a 95% confidence interval (CI) of 1.06-4.01. According to product type, the pooled incidence rates were 0.99 (95% CI 0.37-2.70) per 1000 person-years for patients treated with Advate, 5.86 (95% CI 0.25-134.92) per 1000 person-years for those treated with Kogenate/Helixate, 1.35 (95% CI 0.66-2.77) per 1000 person-years for those treated with Kogenate FS/Helixate NexGen, 12.05 (95% CI 1.53-94.78) per 1000 person-years for those treated with Refacto, and 4.64 (95% CI 0.82-26.43) per 1000 person-years for those treated with Refacto AF. Conclusion These results suggest that some products may be associated with increased immunogenicity. However, the low incidence of inhibitors in PTPs and the differences in study design may cause significant variation in estimates of risk.
引用
- Hassan S, Cannavò A, Gouw SC, et al. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review. J Thromb Haemost. 2018. PMID: 29665204. doi:10.1111/jth.14124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。